Published in AIDS on March 30, 2007
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection | NCT00959894
Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother (2010) 1.08
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr (2011) 1.04
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials (2011) 1.04
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother (2012) 1.00
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos (2012) 0.91
Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Futur HIV Ther (2008) 0.82
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) (2012) 0.76
Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults. Can J Infect Dis Med Microbiol (2009) 0.75
Role of tipranavir in treatment of patients with multidrug-resistant HIV. Ther Clin Risk Manag (2010) 0.75
Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1. HIV AIDS (Auckl) (2010) 0.75
The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection. P T (2011) 0.75
Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection. Core Evid (2010) 0.75
Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci (2005) 16.87
FSL. Neuroimage (2011) 15.56
Probabilistic independent component analysis for functional magnetic resonance imaging. IEEE Trans Med Imaging (2004) 14.60
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A (2009) 9.19
Bayesian analysis of neuroimaging data in FSL. Neuroimage (2008) 9.10
General multilevel linear modeling for group analysis in FMRI. Neuroimage (2003) 7.79
Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage (2004) 6.87
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage (2011) 6.60
Multiplexed echo planar imaging for sub-second whole brain FMRI and fast diffusion imaging. PLoS One (2010) 5.74
The WU-Minn Human Connectome Project: an overview. Neuroimage (2013) 5.49
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Advances and pitfalls in the analysis and interpretation of resting-state FMRI data. Front Syst Neurosci (2010) 3.84
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Extravascular lung water in sepsis-associated acute respiratory distress syndrome: indexing with predicted body weight improves correlation with severity of illness and survival. Crit Care Med (2008) 3.13
Behavioral interpretations of intrinsic connectivity networks. J Cogn Neurosci (2011) 3.09
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Investigating the electrophysiological basis of resting state networks using magnetoencephalography. Proc Natl Acad Sci U S A (2011) 2.69
Pushing spatial and temporal resolution for functional and diffusion MRI in the Human Connectome Project. Neuroimage (2013) 2.68
Imaging how attention modulates pain in humans using functional MRI. Brain (2002) 2.60
Distinct portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward processing in separable phases of decision-making cognition. Biol Psychiatry (2004) 2.58
Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. Brain (2002) 2.57
Meta-analysis of neuroimaging data: a comparison of image-based and coordinate-based pooling of studies. Neuroimage (2008) 2.54
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
Tools of the trade: psychophysiological interactions and functional connectivity. Soc Cogn Affect Neurosci (2012) 2.22
N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON). Crit Care Med (2007) 2.18
Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 2.17
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods (2007) 2.09
Oxidation of methane by a biological dicopper centre. Nature (2010) 2.09
Constrained linear basis sets for HRF modelling using Variational Bayes. Neuroimage (2004) 2.03
An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase. Structure (2004) 1.99
Fully Bayesian spatio-temporal modeling of FMRI data. IEEE Trans Med Imaging (2004) 1.98
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med (2003) 1.98
Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis (2005) 1.97
MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology (2008) 1.96
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med (2003) 1.96
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 1.93
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One (2010) 1.92
Integrity of white matter in the corpus callosum correlates with bimanual co-ordination skills. Neuroimage (2007) 1.92
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis (2005) 1.88
Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner. Neuroimage (2011) 1.88
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis (2013) 1.83
Spectral characteristics of resting state networks. Prog Brain Res (2011) 1.83
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS (2010) 1.83
Structural and functional abnormalities of the motor system in developmental stuttering. Brain (2007) 1.71
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis (2003) 1.71
Primary afferent activation of thermosensitive TRPV1 triggers asynchronous glutamate release at central neurons. Neuron (2010) 1.68
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr (2005) 1.64
Sampling and visualizing creases with scale-space particles. IEEE Trans Vis Comput Graph (2009) 1.61
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 1.60
Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read (2004) 1.60
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol (2012) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Spatially constrained hierarchical parcellation of the brain with resting-state fMRI. Neuroimage (2013) 1.55
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest (2004) 1.53
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis (2010) 1.50
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr (2013) 1.50
Characterization of the particulate methane monooxygenase metal centers in multiple redox states by X-ray absorption spectroscopy. Inorg Chem (2006) 1.50
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A (2013) 1.46
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS (2007) 1.45
Mixture models with adaptive spatial regularization for segmentation with an application to FMRI data. IEEE Trans Med Imaging (2005) 1.43
Manifestations of early brain recovery associated with abstinence from alcoholism. Brain (2007) 1.43
Adjusting the effect of nonstationarity in cluster-based and TFCE inference. Neuroimage (2010) 1.42
When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis (2003) 1.42
Evaluation of slice accelerations using multiband echo planar imaging at 3 T. Neuroimage (2013) 1.42
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis (2003) 1.42
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother (2008) 1.41
Resting state networks change in clinically isolated syndrome. Brain (2010) 1.41
Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. AIDS Read (2007) 1.40
HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest (2003) 1.39
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES). Dermatol Surg (2012) 1.39
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.39
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther (2007) 1.37
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS (2005) 1.37